The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2021 | Second-generation BTK inhibitors and their clinical impact
Deborah M. Stephens, DO, of The University of Utah, Huntsman Cancer Institute, Salt Lake City, UT, discusses second-generation Bruton’s tyrosine kinase inhibitors (BTKis) and outlines the impact that they have had in clinical settings. Dr Stephens compares the toxicity and safety profile of ibrutinib, a first-generation BTKi, with second-generation BTKis such as acalabrutinib and zanubrutinib, suggesting that second-generation BTKis may become a more favourable treatment option. This interview took place during the ninth annual meeting of the Society of Hematologic Oncology (SOHO 2021) congress.
